Novation Holdings Inc. (NOHO)

[MrDemas]

Allezoe Medical Holdings, Inc. (ALZM.OB) Completes Exclusive Licensing Deal for HPV Diagnostic Technology
December 21, 2011 | Filed underHeadline Stocks | Posted by Lead Analyst
Allezoe Medical Holdings, Inc.
6170 Research Road
Suite 103
Frisco, TX 75034-2787
United States - Map
Phone: [phone]
Website: http://www.allezoe.com/

Allezoe Medical Holdings, Inc., a biomedical company, develops, patents, and sells portable hypothermic, oxygenated preservation, and transport technology for human organs. It designs and develops the LifeCradle, which consists of a portable platform and an organ specific disposable set. The company?s primary product, LifeCradle HR Cardiac Perfusion System, perfuses and feeds a heart through a circulating, oxygenated, and hypothermic nutrient solution to preserve and maintain the organ. It is also developing proprietary perfusion solutions for use in the LifeCradle devices. The company was founded in 1999 and is based in Frisco, Texas.


Allezoe Medical Holdings, Inc. (ALZM.OB)
BOCA RATON, FLORIDA–(Marketwire -12/20/11)- Allezoe Medical Holdings, Inc. (OTC.BB: ALZM.OB - News) announces that it has acquired the exclusive license to develop and market patent pending, advanced “see and treat” diagnostic technologyfor Human papillomavirus (HPV), the world’s leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc. Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.

As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking “see and treat” technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.

With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe’s technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.

Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe’s technology is a one-stop HPV solution for patients and their providers. Allezoe’s HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.

Allezoe CEO Michael Gelmon says, “This is not a virus we have the luxury of ignoring, when hundreds of millions of people around the world are affected and are further spreading the virus. Our new licensed technology offers the combination of accuracy plus efficiency. This is a large market that we are looking forward to penetrating, and we have a strategy in place so we can hit the ground running.”



View the full ALZM chart at Wikinvest

Stock recommendations and comments presented on HotPennyStocksOnline.com are solely those of the analysts and experts quoted. They do not represent the opinions of HotPennyStocksOnline.com on whether to buy, sell or hold shares of a particular stock.

Stock closed at the daily high of .04 cents with more than 47 million shares trading hands. The 52 week trading range for (ALZM) has been .01 to $2.64! This stock has traded higher then $2.50 cents before this big news. Look for shares to continue their climb over the next few months. Major updates are coming and the stock is also listed as (OTCQB) a high quality listing on the OTC markets and is a full SEC reporting company with a low float!

The chart is very strong, all technical indicators are pointing up! This could be the next (VMRLQ) that rose more than 100,000%! Merry Christmas everyone!

Once the stock breaks .10 cents a share it will make a run for $1.00 fast. We are placing a short term price target of .55 cents on shares of (ALZM).

Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal or corporate ownership, may influence or factor into an expert’s stock analysis or opinion.

All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is no guarantee of future price appreciation.

Follow your dreams, work hard, practice and persevere. Make sure you eat a variety of foods, get plenty of exercise and maintain a healthy lifestyle.
Sasha Cohen